Home » Posts tagged with » DS-1062
AstraZeneca strikes $6bn worth deal for Daiichi Sankyo’s DS-1062
AstraZeneca has signed a deal potentially worth up to $6 billion with Daiichi Sankyo for the global development and commercialization for the latter’s DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC), which is being developed for the treatment of multiple tumor types. Daiichi Sankyo is developing the antibody drug conjugate for multiple tumors […]
Business News Today
- MedCrypt acquires medical device cybersecurity software firm MedISAO
- Improving acquires custom software development firm Object Partners
- High Street Insurance acquires Michigan-based Capital Insurance Group
- Mill Creek Residential breaks ground on Modera Washington in Houston
- Cincinnati-based RIA Lenox Wealth Management acquired by Creative Planning
- Jersey Elevator acquired by Arcline Investment Management
- U.S. Gold acquires Northern Panther Resource, owner of Challis gold project
- Perrigo acquires skincare and hair loss treatment brands from Sanofi
- Bayer to acquire KaNDy Therapeutics to add menopause drug candidate
- Thoma Bravo to acquire US insurtech Majesco for higher price of $729m
